Comparison of CLL-IPI with MDACC score for prediction of OS and TTFT
| . | Harrel C-index (P) . | AIC . | Chance of being the best model (%) . | Explained variation (P) . |
|---|---|---|---|---|
| Current Italian series (N = 858) | ||||
| Overall survival | ||||
| CLL-IPI | 0.71 (<.001) | 1870.05 | 99 | 23% (<.001) |
| MDACC score | 0.68 (<.001) | 1878.40 | 1 | 21% (<.001) |
| Time to first treatment | ||||
| CLL-IPI | 0.72 (<.001) | 2155.80 | 99 | 42% (<.001) |
| MDACC score | 0.63 (<.001) | 2225.64 | 1 | 22% (<.001) |
| Mayo Clinic series (N = 506) | ||||
| Overall survival | ||||
| CLL-IPI | 0.75 (<.001) | 1189.05 | 99 | 38% (<.001) |
| MDACC score | 0.66 (<.001) | 1251.01 | 1 | 20% (<.001) |
| Time to first treatment | ||||
| CLL-IPI | 0.74 (<.001) | 3467.39 | 99 | 42% (<.001) |
| MDACC score | 0.66 (<.001) | 3546.29 | 1 | 31% (<.001) |
| . | Harrel C-index (P) . | AIC . | Chance of being the best model (%) . | Explained variation (P) . |
|---|---|---|---|---|
| Current Italian series (N = 858) | ||||
| Overall survival | ||||
| CLL-IPI | 0.71 (<.001) | 1870.05 | 99 | 23% (<.001) |
| MDACC score | 0.68 (<.001) | 1878.40 | 1 | 21% (<.001) |
| Time to first treatment | ||||
| CLL-IPI | 0.72 (<.001) | 2155.80 | 99 | 42% (<.001) |
| MDACC score | 0.63 (<.001) | 2225.64 | 1 | 22% (<.001) |
| Mayo Clinic series (N = 506) | ||||
| Overall survival | ||||
| CLL-IPI | 0.75 (<.001) | 1189.05 | 99 | 38% (<.001) |
| MDACC score | 0.66 (<.001) | 1251.01 | 1 | 20% (<.001) |
| Time to first treatment | ||||
| CLL-IPI | 0.74 (<.001) | 3467.39 | 99 | 42% (<.001) |
| MDACC score | 0.66 (<.001) | 3546.29 | 1 | 31% (<.001) |